U.S. manufacturers are sharply increasing production of cheap, fast – but less accurate – Covid-19 tests, aiming for 100 million per month by year-end 2020 that will enable schools and workplaces to significantly expand testing.
European efforts to secure potential COVID-19 vaccines from Pfizer, Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.
The U.S. government set a benchmark for COVID-19 vaccine pricing that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.
Twenty-six drug manufacturers were sued by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices.
New York’s insurance regulator formally notified a group of opioid manufacturers and distributors that the NYDFS will launch a civil enforcement action against them for contributing towards a rise in health insurance premiums in the state, said two sources familiar with the matter.
Pharma companies may not like their products being the subject of ICER reports, but they can provide a jumping-off point for manufacturers to expand the conversation of the value of new medicines in the rare disease area.
The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.
EVERSANA, the leading independent provider of global services to the life science industry, introduced a new suite of global market access solutions from Health Strategies Insights to help biopharmaceutical manufacturers understand the latest global trends in access, payment, distribution and administration.
As lawmakers in Congress are exploring potential price-lowering options for prescription drugs, Department of Health and Human Services Secretary Alex Azar is floating a proposed rule to lower the prices and out-of-pocket expenses by encouraging manufacturers to pass discounts to patients instead of insurers.
The difficulty behind new ideas, project management, drug prices, and the slowness and uncertainty of new product development are just some external and internal roadblocks that pharmaceutical leaders and employees face.